Provider portal features an updated enrollment form, and potential for a 60-second benefit verification.
Regeneron Pharmaceuticals is now offering EYLEA4U Connect, featuring an updated enrollment form, and potential for a 60-second benefit verification.
According to the company, an EYLEA4U Connect enrollment can help more than 40% of patients receive a benefit verification within 60 seconds for a faster time to treatment, and a better patient experience.
The company noted in a press release that EYLEA4U “will provide either a full benefit verification or notification that manual processing is required.”
Manual processing could take up to 48 hours, according to the press release.
Regeneron’s EYLEA4U provides patient support for Eylea injections. The Eylea (aflibercept) Injection is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, or known hypersensitivity to aflibercept or to any of the excipients in EYLEA.
For patients with commercial insurance not funded through the U.S. government, EYLEA4U may offset some out-of-pocket co-pay costs.
Patients with insurance through a government healthcare program such as Medicare or Medicare Advantage can be referred to an independent charitable foundation designed to help patients pay for medications. An EYLEA4U specialist will not only refer patients to a charitable foundation, they will follow up with the foundation until a decision is made on the application.
For patients without insurance or whose insurance does not cover Eylea injections, EYLEA4U may be able to provide the drug free of charge. Regeneron also offers patients the EYLEA Injection Co-Pay Card Program.